API Solutions

Dr. Reddy's API business supplies high-quality, affordable APIs to leading generic formulations manufacturers and is the preferred API partner for pharma companies in more than 100 countries.

R&D

Dr. Reddy’s supplies generic APIs to 80+ countries, excelling in R\&D across niche molecules and key therapies, with capabilities from lab to production in contained/non-contained APIs and advanced chemical processes.

White Paper

Dr. Reddy’s offers insightful whitepapers sharing expertise on APIs, formulations, regulatory trends, and industry innovations, helping global pharma partners gain knowledge, solve challenges, and drive faster, compliant product development.

About Iptacopan API

Therapeutic Category Haematology/Nephrology
CAS Number
1644670‑37‑0
API Technology
Small‑molecule synthetic API
Dose Form
Oral Solid/Capsules
Dr Reddy's Development Status
Under Development

Mechanism of action

Iptacopan binds to complement factor B (FB), a key component of the alternative complement pathway.
This inhibits formation of the C3 convertase (C3bBb), thereby:

Reducing C3 cleavage and C3b generation
Preventing downstream formation of C5 convertase and the membrane attack complex (MAC)

By acting upstream (proximal) in the complement cascade, iptacopan controls:

C3b‑mediated extravascular hemolysis
Terminal complement‑mediated intravascular hemolysis

Importantly, it selectively blocks the alternative pathway, leaving the classical and lectin pathways intact to preserve host immune defense.

Indication

Approved indications (FDA / EMA):

Paroxysmal nocturnal hemoglobinuria (PNH) in adults
Reduction of proteinuria in adults with primary IgA nephropathy (IgAN) at risk of rapid disease progression
Complement 3 glomerulopathy (C3G) to reduce proteinuria